

*Supplementary material for Zilli T. et al. Dose-adapted salvage radiotherapy after radical prostatectomy based on an erMRI target definition model: Toxicity analysis, Acta Oncologica, 2013;53:96–102.*

Supplementary Table I. Comparative late toxicity results of SRT series.

Reference	N	Median FU (months)	RT technique	Median RT dose (Gy)	Pelvic RT (%)	ADT use (%)	Toxicity scale	Late toxicity grade ≥ 2 (%)		Late toxicity grade ≥ 3 (%)	
								GU	GI	GU	GI
Neuhof et al. [17]	171	39	3D-CRT	63	0	29	RTOG	13.4 <sup>a</sup>	NR	4.7 <sup>a</sup>	0
Feng et al. [13]	777	55	2D-RT/ 3D-CRT	64	22	15	RTOG	11.2 <sup>a</sup>	4.7 <sup>a</sup>	1.2 <sup>a</sup>	0.7 <sup>a</sup>
Chawla et al. [11]	54	45	2D-RT	64.8	0	0	RTOG	13 <sup>a</sup>	NR	3.7 <sup>a</sup>	0
Wiegel et al. [19]	162	41.5	3D-CRT	66 (90%)	0	0	RTOG	3.7 <sup>a</sup>	3.1 <sup>a</sup>	2.4 <sup>a</sup>	0
Jereczek-Fossa et al. [15]	173	30	3D-CRT	70	0	55.5	RTOG	4.8 <sup>a</sup> /10.6 <sup>b</sup>	6.6 <sup>a</sup>	0.6 <sup>a</sup>	0.6 <sup>a</sup>
Goenka et al. [14]	285	60	3D-CRT (38%)/ IMRT (62%)	< 70 (38%) ≥ 70 (72%)	7	30	CTCAE	17 <sup>b</sup>	5.2 <sup>b</sup>	NR	1.4 <sup>a</sup>
Kruser et al. [16]	108	32.4	IMRT/HT	65 (26 fx) <sup>c</sup>	0	17	RTOG/Fox Chase CTCAE	15 <sup>a</sup>	4 <sup>a</sup>	0	0
Cozzarini et al. [12]	186	92	2D-RT/ 3D-CRT	≤ 72 (59%) > 72 (41%)	17	67	CTCAE	23.7 <sup>c</sup>	NA	6 <sup>c</sup>	NA
Ost et al. [15]	136	60	IMRT	76	0	71	In-house scale	22 <sup>b</sup>	8 <sup>b</sup>	3 <sup>a</sup>	1.3 <sup>a</sup>
Current series	109	47	3D-CRT (93%)/ IMRT (7%)	64 (25%) 74 (75%)	22	20	RTOG	16.1 <sup>d</sup>	12.9 <sup>d</sup>	3.6 <sup>a</sup>	0 <sup>a</sup>
										8.5 <sup>a</sup>	2.4 <sup>a</sup>

ADT, androgen deprivation therapy; CTCAE, Common Terminology Criteria for Adverse Event toxicity scale; FU, follow-up; GI, gastrointestinal; GU, genitourinary; HT, helical tomotherapy; IMRT, intensity-modulated radiotherapy; NA, not assessed; NR, not reported; RTOG, Radiation Therapy Oncology Group; 3D-CRT, three-dimensional conformal radiotherapy.

<sup>a</sup>Crude value; <sup>b</sup>5-year actuarial risk; <sup>c</sup>8-year actuarial risk; <sup>d</sup>4-year actuarial risk; <sup>e</sup>Normalized total dose in 2-Gy fraction = 71.5 Gy ( $\alpha/\beta = 3$  Gy for late responding tissues).